Prices are updated after-hours
Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
positive   save search
IN8bio to Present Positive Early Data from Ongoing Phase 1 Study of INB-100 at the 64th American Society of Hematology Annual Meeting
Published: 2022-11-03 (Crawled : 13:00) - globenewswire.com
INAB | $0.9901 -2.93% 160K twitter stocktwits trandingview |
| | O: -10.75% H: 19.82% C: 12.89%
inb-100 ongoing meeting positive study phase 1
Abeona Therapeutics Announces Positive Topline Results with Both Co-Primary Endpoints Met in Pivotal Phase 3 VIITAL™ Study of EB-101
Published: 2022-11-03 (Crawled : 12:20) - biospace.com/
ABEO | $7.85 2.75% 120K twitter stocktwits trandingview |
Health Technology
 | | O: 0.9% H: 2.22% C: -14.0%
eb-101 topline therapeutics positive results study
New Report from GoodRx Shows Positive Impact of Giving Pharmacists the Power to Prescribe
Published: 2022-11-03 (Crawled : 12:00) - biospace.com/
GDRX 4 | $6.655 1.6% 600K twitter stocktwits trandingview |
Technology Services
 | | O: -1.6% H: 0.81% C: -0.41%
report impact positive
REGENXBIO Presents Positive Interim Data from and the Expansion of Phase II ALTITUDE® Trial of RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery
Published: 2022-11-03 (Crawled : 12:00) - biospace.com/
RGNX | $17.84 -1.0% 73K twitter stocktwits trandingview |
Health Technology
 | | O: -3.01% H: 0.77% C: -10.46%
CLSD | $1.2 -6.98% 290K twitter stocktwits trandingview |
Health Technology
 | | O: 0.74% H: 11.76% C: 7.35%
rgx-314 altitude treatment expansion trial positive diabetic
Athenex Announces Receipt of Positive Nasdaq Listing Determination
Published: 2022-11-03 (Crawled : 11:00) - globenewswire.com
ATNX | $0.2031 -7.78% 1.9M twitter stocktwits trandingview |
Health Technology
 | | O: 1.63% H: 2.45% C: 0.0%
nasdaq positive
Transgene Announces Positive Interim Analysis Results of Phase II Trial Evaluating TG4001 + Avelumab vs Avelumab in HPV-Positive Anogenital Cancers
Published: 2022-11-02 (Crawled : 00:00) - biospace.com/
PFE A | $25.73 -0.7% 17M twitter stocktwits trandingview |
Health Technology
 | | O: -0.5% H: 0.84% C: -1.47%
tg4001 trial positive results
10-Q: Quarterly report which provides a continuing view of a company's financial position
Published: 2022-11-02 (Crawled : 21:00) - allogene.com
ALLO | $3.515 -0.99% 890K twitter stocktwits trandingview |
Health Technology
 | | O: -7.47% H: 4.2% C: 1.17%
report financial
Can-Fite: Positive New Data from it’s Phase III Psoriasis Study will be Presented Today at an Industry Expert Summit in Boston
Published: 2022-11-02 (Crawled : 12:00) - biospace.com/
CANF | $2.095 1.21% 11K twitter stocktwits trandingview |
Health Technology
 | | O: 1.1% H: 0.0% C: -0.64%
psoriasis positive today study
Photocure ASA: Results for the third quarter of 2022 Photocure ASA reported Hexvix®/Cysview® revenues of NOK 96.9 million in the third quarter of 2022, up 12% compared to Q3 2021, and positive EBITDA o...
Published: 2022-11-02 (Crawled : 10:00) - biospace.com/
VRNA | $16.29 3.1% 380K twitter stocktwits trandingview |
Health Technology
 | | O: 1.21% H: 1.87% C: -2.88%
hexvix positive
Akston Biosciences Announces Positive Interim Phase II Results from COVID “Universal” Booster Vaccine Trial
Published: 2022-11-01 (Crawled : 17:00) - biospace.com/
JNJ | $145.405 -1.48% 7.6M twitter stocktwits trandingview |
Health Technology
 | | O: -0.36% H: 0.0% C: 0.0%
covid vaccine trial positive results
Pfizer Announces Positive Top-Line Data of Phase 3 Global Maternal Immunization Trial for its Bivalent Respiratory Syncytial Virus (RSV) Vaccine Candidate
Published: 2022-11-01 (Crawled : 12:00) - biospace.com/
PFE A | $25.73 -0.7% 17M twitter stocktwits trandingview |
Health Technology
 | | O: 3.11% H: 0.88% C: 0.02%
candidate global vaccine respiratory virus trial positive
Pharmazz Inc. Presents Positive Results of Phase III Clinical Trial Demonstrating Sovateltide’s Efficacy as a Treatment for Acute Cerebral Ischemic Stroke
Published: 2022-10-31 (Crawled : 17:00) - biospace.com/
AZZ | $76.43 -0.65% 32K twitter stocktwits trandingview |
Producer Manufacturing
 | | O: -1.15% H: 2.4% C: 1.72%
treatment stroke trial positive
Bristol Myers Squibb Announces Positive Topline Results of Phase 3 COMMANDS Trial
Published: 2022-10-31 (Crawled : 16:00) - biospace.com/
BMY | $48.365 -0.3% 4.9M twitter stocktwits trandingview |
Health Technology
 | | O: -0.31% H: 2.7% C: 1.15%
topline trial positive results
Ensysce Biosciences Announces Positive Topline Results of Clinical Study Evaluating Human Abuse Potential of Intranasal Administration of PF614, a TAAP Abuse-Deterrent Oxycodone Extended-Release Product
Published: 2022-10-31 (Crawled : 15:00) - biospace.com/
ENSC | $0.6352 -6.52% 52K twitter stocktwits trandingview |
Health Technology
 | | O: -2.32% H: 0.26% C: -14.78%
pf614 topline potential positive results study
HOTH THERAPEUTICS REPORTS POSITIVE BIOLEXA PHASE 1B CLINICAL TRIAL RESULTS IN MILD TO MODERATE ATOPIC DERMATITIS
Published: 2022-10-31 (Crawled : 14:20) - prnewswire.com
HOTH | $1.18 -1.67% 47K twitter stocktwits trandingview |
Health Technology
 | | O: -0.44% H: 39.57% C: -1.06%
dermatitis trial therapeutics positive results phase 2b
KalVista Pharmaceuticals Announces Positive Phase 1 Data for Orally Disintegrating Tablet Formulation of Sebetralstat for Use in Hereditary Angioedema
Published: 2022-10-31 (Crawled : 11:00) - ir.kalvista.com
KALV | $12.0 2.22% 140K twitter stocktwits trandingview |
Health Technology
 | | O: -2.74% H: 4.91% C: 2.01%
pharmaceuticals positive sebetralstat hereditary angioedema phase 1
Loews Corporation announces management changes at Loews Hotels & Co: Jonathan Tisch to assume Executive Chairman Position; Alex Tisch to become President and CEO
Published: 2022-10-31 (Crawled : 11:00) - prnewswire.com
L 4 | $73.55 0.15% 240K twitter stocktwits trandingview |
Finance
 | | O: -1.28% H: 1.03% C: -0.4%
management ceo hotels corporation
Actinium Announces Positive Top-line Results from Pivotal Phase 3 SIERRA Trial of Iomab-B in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia
Published: 2022-10-31 (Crawled : 11:00) - biospace.com/
ATNM | $8.0 -5.21% 170K twitter stocktwits trandingview |
Health Technology
 | | O: 6.06% H: 34.59% C: 31.2%
active leukemia trial positive results acute myeloid leukemia
Nuvalent Reports Preliminary Phase 1 Clinical Data from ARROS-1 Trial that Support Best-In-Class Potential of NVL-520 for Patients with ROS1-Positive NSCLC
Published: 2022-10-28 (Crawled : 05:00) - prnewswire.com
NUVL | $65.155 -0.19% 410K twitter stocktwits trandingview |
| | O: 42.89% H: 0.0% C: 0.0%
nvl-520 trial potential phase 1
KAZIA'S PAXALISIB DEMONSTRATES POSITIVE MONOTHERAPY EFFICACY SIGNALS IN PRECLINICAL MODELS OF MELANOMA
Published: 2022-10-27 (Crawled : 18:00) - biospace.com/
KZIA | $0.274 -10.75% 260K twitter stocktwits trandingview |
Health Technology
 | | O: 24.14% H: 4.76% C: -21.43%
melanoma preclinical paxalisib positive
Gainers vs Losers
55% 45%

Top 10 Gainers
WISA 4 | $5.33 204.57% 190M twitter stocktwits trandingview |
Electronic Technology
TPET | $0.5189 124.54% 38M twitter stocktwits trandingview |
n/a
SXTC | $1.78 52.14% 33M twitter stocktwits trandingview |
Health Technology
JAGX | $0.1771 49.07% 540M twitter stocktwits trandingview |
Health Technology
DYNT | $0.52 40.39% 20M twitter stocktwits trandingview |
Health Technology
BSGM | $1.53 39.09% 2.6M twitter stocktwits trandingview |
Health Technology
MCBC | $13.74 38.37% 1.6M twitter stocktwits trandingview |
Finance
FNCH | $2.98 32.74% 400K twitter stocktwits trandingview |
Professional, Scientific, and T...
PALI | $5.51 32.45% 28M twitter stocktwits trandingview |
Manufacturing
VERO | $0.804 31.8% 110K twitter stocktwits trandingview |
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.